TY - JOUR

T1 - Application of advanced brain positron emission tomography–based molecular imaging for a biological framework in neurodegenerative proteinopathies

AU - Perani, Daniela

AU - Iaccarino, Leonardo

AU - Jacobs, Andreas H.

AU - Lammertsma, Adriaan A.

AU - Nordberg, Agneta

AU - Windhorst, Albert D.

AU - Gerhard, Alexander

AU - Winkeler, Alexandra

AU - Gee, Anthony

AU - Kuhnast, Bertrand

AU - Halldin, Christer

AU - Brooks, David

AU - Rodriguez-Vieitez, Elena

AU - Turkheimer, Federico E.

AU - López-Picón, Francisco

AU - Knudsen, Gitte M.

AU - Vercouillie, Johnny

AU - Rinne, Juha O.

AU - Herholz, Karl

AU - Van Laere, Koen

AU - Santiago-Ribeiro, Marie Joao

AU - Herth, Matthias M.

AU - Carroll, Michael A.

AU - Bottlaender, Michel

AU - Hansson, Oskar

AU - Edison, Paul

AU - Hinz, Rainer

AU - Boellaard, Ronald

AU - Moresco, Rosa Maria

AU - Pappata, Sabina

AU - IMBI Brain Imaging Working Group

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Introduction: A rapid transition from a clinical-based classification to a pathology-based classification of neurodegenerative conditions, largely promoted by the increasing availability of imaging biomarkers, is emerging. The Framework for Innovative Multi-tracer molecular Brain Imaging, funded by the EU Joint Program - Neurodegenerative Disease Research 2016 “Working Groups for Harmonisation and Alignment in Brain Imaging Methods for Neurodegeneration,” aimed at providing a roadmap for the applications of established and new molecular imaging techniques in dementia. Methods: We consider current and future implications of adopting a pathology-based framework for the use and development of positron emission tomography techniques. Results: This approach will enhance efforts to understand the multifactorial etiology of Alzheimer's disease and other dementias. Discussion: The availability of pathology biomarkers will soon transform clinical and research practice. Crucially, a comprehensive understanding of strengths and caveats of these techniques will promote an informed use to take full advantage of these tools.

AB - Introduction: A rapid transition from a clinical-based classification to a pathology-based classification of neurodegenerative conditions, largely promoted by the increasing availability of imaging biomarkers, is emerging. The Framework for Innovative Multi-tracer molecular Brain Imaging, funded by the EU Joint Program - Neurodegenerative Disease Research 2016 “Working Groups for Harmonisation and Alignment in Brain Imaging Methods for Neurodegeneration,” aimed at providing a roadmap for the applications of established and new molecular imaging techniques in dementia. Methods: We consider current and future implications of adopting a pathology-based framework for the use and development of positron emission tomography techniques. Results: This approach will enhance efforts to understand the multifactorial etiology of Alzheimer's disease and other dementias. Discussion: The availability of pathology biomarkers will soon transform clinical and research practice. Crucially, a comprehensive understanding of strengths and caveats of these techniques will promote an informed use to take full advantage of these tools.

KW - Amyloid

KW - Neuroinflammation

KW - PET molecular imaging

KW - Protheinopathies

KW - Radiotracers

KW - Tau

U2 - 10.1016/j.dadm.2019.02.004

DO - 10.1016/j.dadm.2019.02.004

M3 - Journal article

C2 - 31080871

AN - SCOPUS:85064440586

VL - 11

SP - 327

EP - 332

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

SN - 2352-8729

ER -